Back to search

France· FR:69201938

TEVIMBRA 100 mg, solution à diluer pour perfusion

A tislelizumab product containing tislélizumab, registered in France by BEONE MEDICINES IRELAND (IRLANDE). The same ATC class is registered in 12 of our 19 countries.

ATC L01FF09

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedTEVIMBRA 100 mg, solution à diluer po…ATCL01FF09REGISTER NO.FR:69201938PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Tislelizumab is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FF09 (tislelizumab), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose

Tislelizumab · ATC L01FF09

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of tislelizumab costs, country by country.

Normalised to the WHO defined daily dose (9.5 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Tislelizumab · price per daily dose (9.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$204.40
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
TISLÉLIZUMAB
Manufacturer
BEONE MEDICINES IRELAND (IRLANDE)
Country
France (FR)
ATC code
L01FF09
ATC class
Tislelizumab
Defined daily dose
9.5 mg, P
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400955101628
    1 flacon en verre de 10 mL

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Tislelizumab in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tislelizumab products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Tevimbra
  • Norway · Tevimbra

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/91515757-4276-4111-b372-b42e5583175a
GET /v1/drugs/91515757-4276-4111-b372-b42e5583175a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "69201938",
  "date_amm": "2023-09-15",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/23/1758",
  "substance": "TISLÉLIZUMAB",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution à diluer pour perfusion",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Oui"
}

See everything about tislelizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.